C13H11N3O4 Pomalidomide 19171-19-8 CAS NO.19171-19-8

Min.Order Quantity:: 1 Metric Ton

Purity:: 99.5%

Port:: Any port of China

Payment Terms:: L/C,T/T,

Add to Inquiry Cart

Product Details

Keywords

Pomalidomide
19171-19-8
C13H11N3O4

Quick Details

ProName: C13H11N3O4 Pomalidomide 19171-19-8
CasNo: 19171-19-8
Molecular Formula: C13H11N3O4
Appearance: Powder
Application: 19171-19-8 ...
DeliveryTime: by air
PackAge: Aluminium Foil Bag and Paper Drum
Port: Any port of China
ProductionCapacity: 100 Metric Ton/Day
Purity: 99.5%
Storage: 1MT
Transportation: By Sea/Air/DHL
LimitNum: 1 Metric Ton
Grade: Industrial Grade,Food Grade,Pharma Gra...

Superiority

our company was built in 2009 with an iso certificate.in the past 5 years, we have grown up as a famous fine chemicals supplier in china and we had established stable business relationships with samsung,lg,merck,thermo fisher scientific and so on.our main business covers the fields below:

1.noble metal catalysts (pt.pd...)

2.organic phosphine ligands (tert-butyl-phosphine.cyclohexyl-phosphine...)

3.oled intermediates (fluorene,carbazole,boric acid...)

4.customs synthesis

our advantage:

1. higest quality and good package

2.fast delivery

3.better payment term

4.fast response to customer within 6 hours

5.good business credit in europe ,us ,japan ,korea

anyway ,if you need any chemicals from china ,henan tianfu can help you

Details

pomalidomide basic information

description in vitro in vivo

product name:	pomalidomide
synonyms:	3-amino-n-(2,6-dioxo-3-piperidyl)phthalimide;4-amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione;pomalidomide;pomalidomide(cc-4047);actimid;cc-4047;4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;1h-isoindole-1,3(2h)-dione,4-amino-2-(2,6-dioxo-3-piperidinyl)-
cas:	19171-19-8
mf:	c13h11n3o4
mw:	273.24
einecs:
product categories:	inhibitor;cc-4047;inhibitors
mol file:	19171-19-8.mol

pomalidomide chemical properties

melting point	318.5 - 320.5°
storage temp.	2-8°c
solubility	dmso: ≥14mg/ml
color	yellow
merck	14,135

safety information

rtecs

nr3397905

msds information

pomalidomide usage and synthesis

description	pomalidomide inhibits lps-induced tnf-α release with ic50 of 13 nm in pbmcs.
in vitro	pomalidomide inhibits lipopolysaccharide (lps) stimulated tnf-alpha release in human pbmc and in human whole blood with ic50 values of 13 nm and 25 nm, respectively. pomalidomide inhibits the growth of t regulatory cells which is stimulated by il-2 with an ic50 of ~1 μm. treatment with pomalidomide (6.4 nm-10 μm) increases the production of il-2 in human peripheral blood t cells, and is slightly more potent in the cd4+ subset than in the cd8+ subset. pomalidomide is significantly more potent than cc-5013 at elevating il-2, il-5, and il-10 levels, but only slightly more potent than cc-5013 at elevating ifn-γ levels. pomalidomide enhances see and raji cells induced ap-1 transcriptional activity in jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μm. exposure of raji cells to various concentrations of pomalidomide (2.5-40 μg/ml) for 48 hours leads to a significant decrease in cell proliferation and dna synthesis. there is a reduction of ~40% compared to vehicle-treated controls.
in vivo	pomalidomide enhances the antitumor effect of rituximab against b-cell lymphomas in severe combined immunodeficient mice. administration of pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of cc5013/rituximab treatment and 45 days of rituximab nonotherapy. the synergistic effect of pomalidomide and rituximab can be completely abrogated by depletion of nk cells, supporting the proposal that nk cell expansion is one mechanism by which pomalidomide may augment rituximab antitumor activity.
chemical properties	yellow solid
uses	pomalidomide is a thalidomide derivative, a potent inhibitor of tnf-α production. it is an antiinflammatory and antitumor agent used in the treatment of multiple myeloma.
uses	pomalidomide is a second generation immunomodulator, tnf-α inhibitor, and thalidomide analog. an inhibitor of lps-induced tnfαrelease.
uses	pomalidomide inhibits lps-induced tnf-α release with ic50 of 13 nm
definition	chebi: an aromatic amine that is thalidomide substituted at position 4 on the isoindole ring system by an amino group. used for the treatment of multiple myeloma in patients who failed to respond to previous therapies.